Stefan A J Buck

5PUBLICATIONS
27CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 16, 2024
Darolutamide does not interfere with OATP-mediated uptake of docetaxel.

Stefan A J Buck, Zahra Talebi, Thomas Drabison

|Nov 29, 2023
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.

Stefan A J Buck, Annelies Van Hemelryk, Corrina de Ridder

|Mar 14, 2023
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.

Aurelius Omlin, Richard Cathomas, Gunhild von Amsberg

|Jul 27, 2022
Influence of Darolutamide on Cabazitaxel Systemic Exposure.

Stefan A J Buck, Niels A D Guchelaar, Peter de Bruijn

|Mar 24, 2022
Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.

Stefan A J Buck, C Louwrens Braal, Maaike M Hofman

Pageof 1